Assorted News from the Last Week: Two articles of interest about childhood and AYA cancer survivorship: Microvascular skeletal muscle oxygenation linked to exercise capacity in
Assorted News from the Last Week: Accelerated brain aging, atherogenicity, and neurocognition in adult survivors of childhood cancer. The FDA has approved narsoplimab-wuug (Yartemlea) for
Assorted News from the Last Week: Study reveals the profound psychological burden borne not only by childhood cancer survivors but also by their parents, including
Assorted News from the Last Week: CAC2 Board Member Aubrey Reichard-Eline of WITH Grace Initiatives pens powerful Op Ed: “Turning pain into purpose: how service
Assorted News from the Last Week: CAC2 Member Braden’s Hope for Childhood Cancer funds new program to help childhood cancer survivors as they enter adulthood.
Assorted News from the Last Week: American Association for Cancer Research released the AACR Pediatric Cancer Progress Report 2025. Among the trends highlighted: Between 2015 and
Assorted News from the Last Week: Drug combination sidesteps resistance in aggressive childhood neuroblastoma models. Study results suggest that apatinib plus IE may improve PFS
Assorted News from the Last Week: This edition of the CAC2 blog post provides a compassionate guide to embracing bereaved families during the holidays. Columbia
Assorted News from the Last Week: The impact of focused federal initiatives on pediatric cancer research: continuous support for both CCDI and the STAR Act
Assorted News from the Last Week: CAC2 Supporting Organization Member Syndax Pharmaceuticals announced that the Food and Drug Administration approved revumenib, a menin inhibitor, for
